Patty Harris has over 20 years of global clinical development experience across a variety of oncology/hematology indications. Prior to joining KSQ, Patty was Vice President of Clinical Sciences at Cogent Biosciences and at Unum Therapeutics where she led the clinical development for small molecule and modified autologous cellular therapies.  She has worked at both emerging and large biotechnology companies where she managed a number of clinical development functions and helped build clinical infrastructure.  While at Infinity Pharmaceuticals, she was the clinical science lead for the clinical development of duvelisib (Copiktra) which received marketing approval for CLL and follicular lymphoma. At Pfizer, Patty was the global clinical program lead and clinical submissions lead for bosutinib (Bosulif) providing clinical strategy and execution guidance from phase 1 through pivotal registration trials. She received her Master’s in Public Health from Boston University and her Bachelor’s degree from The College of the Holy Cross.